Hormone replacement therapy and malignancy

Affiliations

Review

C T Fitzgerald et al. Br J Obstet Gynaecol. 1993 May.

. 1993 May;100(5):408-10.

doi: 10.1111/j.1471-0528.1993.tb15262.x.

¹ Department of Obstetrics & Gynaecology, University Hospital of South Manchester, West Didsbury.

No abstract available

Similar articles

Hormone replacement and cancer.
Barrett-Connor E. Barrett-Connor E. Br Med Bull. 1992 Apr;48(2):345-55. doi: 10.1093/oxfordjournals.bmb.a072550. Br Med Bull. 1992. PMID: 1450874 Review.
Hormone replacement therapy and cancer.
Mack TM. Mack TM. Baillieres Clin Endocrinol Metab. 1993 Jan;7(1):113-49. doi: 10.1016/s0950-351x(05)80273-3. Baillieres Clin Endocrinol Metab. 1993. PMID: 8435049 Review. No abstract available.
Estrogen use and cancer incidence: a review.
Lupulescu A. Lupulescu A. Cancer Invest. 1995;13(3):287-95. doi: 10.3109/07357909509094464. Cancer Invest. 1995. PMID: 7743382 Review. No abstract available.
Hormone replacement therapy and female malignancy: what has the Million Women Study added to our knowledge?
Marsden J. Marsden J. J Fam Plann Reprod Health Care. 2007 Oct;33(4):237-43. doi: 10.1783/147118907782101869. J Fam Plann Reprod Health Care. 2007. PMID: 17925102 No abstract available.
[Hormone replacement therapy in menopause: continue or stop the prescription after 10 years? There are reasons to continue hormone replacement therapy longer than 10 years].
Rozenbaum H. Rozenbaum H. Gynecol Obstet Fertil. 2002 Sep;30(9):723-32. doi: 10.1016/s1297-9589(02)00421-6. Gynecol Obstet Fertil. 2002. PMID: 12448371 French. No abstract available.